Loading...

US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide

Published
09 Apr 25
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-13.5%
7D
-5.4%

Author's Valuation

SEK 12.860.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Increased 20%

Shared on 24 Apr 25

Fair value Decreased 26%

AnalystConsensusTarget has decreased revenue growth from 91.1% to 80.9%, decreased profit margin from 20.2% to 10.3% and increased future PE multiple from 27.9x to 54.0x.

Shared on 17 Apr 25

Fair value Increased 30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.